Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Repare Therapeutics's enterprise value is $1.98 Mil.
Repare Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-76.46 Mil. Therefore, Repare Therapeutics's EV-to-EBITDA for today is -0.03.
The historical rank and industry rank for Repare Therapeutics's EV-to-EBITDA or its related term are showing as below:
RPTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.26 Med: -0.57 Max: 27.19
Current: -0.03
During the past 8 years, the highest EV-to-EBITDA of Repare Therapeutics was 27.19. The lowest was -23.26. And the median was -0.57.
RPTX's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 13.94
vs RPTX: -0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Repare Therapeutics's PE Ratio (TTM) for today is calculated as:
Repare Therapeutics's share price for today is $2.65.
Repare Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Repare Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Repare Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's EV-to-EBITDA falls into.
Repare Therapeutics's current Enterprise Value is $1.98 Mil.
Repare Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repare Therapeutics (RPTX) has a EV-to-EBITDA of -0.03 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Repare Therapeutics.
Is Repare Therapeutics' EV-to-EBITDA too high?
Repare Therapeutics' current EV-to-EBITDA is -0.03. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' EV-to-EBITDA compare to MGNX and THAR?
Repare Therapeutics' EV-to-EBITDA of -0.03 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.94, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Repare Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repare Therapeutics's current EV-to-EBITDA is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current EV-to-EBITDA of -0.03. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current EV-to-EBITDA is -0.03. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current EV-to-EBITDA is -0.03 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repare Therapeutics (RPTX) Overvalued in 2026?
Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued.
The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.
Key valuation signals for RPTX:
EV-to-EBITDA: -0.03
GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score
Get the complete analysis for RPTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPTX has been successfully added to your 
